A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Clinical trial NCT04335006 · TERMINATED
Trial details
- NCT number
- NCT04335006
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-14
- Primary completion
- 2023-04-14
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.